Open AccessProgrammed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
Author(s) -
Soomin Ahn,
Ji Won Woo,
Hyojin Kim,
Eun Yoon Cho,
Ahrong Kim,
Jee Yeon Kim,
Chungyeul Kim,
Min Cheol Chang,
Ji Shin Lee,
Young Kyung Bae,
Youngmee Kwon,
Wan Seop Kim,
So Yeon Park
Publication year - 2021
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2021.24.e29
Subject(s) - concordance , medicine , immunohistochemistry , breast cancer , pathology , triple negative breast cancer , oncology , cancer
The programmed death ligand 1 (PD-L1) SP142 assay with a 1% immune cell (IC) cutoff is approved for the selection of advanced triple-negative breast cancer (TNBC) patients for atezolizumab treatment. We aimed to evaluate the interobserver concordance of PD-L1 scoring and inter-assay variability of various PD-L1 assays in TNBC.